Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients

Table 1 Clinicopathological features and the expression of lysine specific demethylase 1 in 198 hepatocellular carcinoma patients

Characteristics	n	LSD1 (%)		P value
		High expression	Low expression
Gender
Male	101	58	43
Female	97	54	43	NS
Age (yr)
≥ 50	112	61	51
< 50	86	51	35	NS
Tumor stage
T1	39	5	34
T2	42	21	21
T3	76	47	29
T4	41	39	2	< 0.001
Tumor grade
G1	45	9	34
G2	114	63	51
G3	39	38	1	< 0.001
Growth pattern
Trabecular	147	84	63
Nontrabecular	51	28	23	NS
Cirrhosis
Yes	151	87	64
No	47	25	22	NS
Underlying liver disease
Alcoholic	21	15	6
Hepatitis B	136	74	62
Hepatitis C	30	17	13
Unknown	11	6	5	NS

LSD1: Lysine specific demethylase 1; NS: Not significant.

Table 2 Multivariate survival analysis of five-year overall and disease-free survival in 198 patients with hepatocellular carcinoma

Parameter	Five-year overall survival			Five-year disease-free survival
	P value	HR	95%CI	P value	HR	95%CI
Age	0.775	0.867	0.463-1.452	0.714	1.174	0.883-1.853
Gender	0.456	1.121	0.569-1.867	0.634	1.126	0.684-1.846
Tumor stage	< 0.001	1.634	1.142-2.537	< 0.001	1.423	0.784-2.161
Tumor grade	< 0.001	1.154	0.647-1.893	< 0.001	1.023	0.456-1.638
Presence of cirrhosis	0.542	1.143	0.647-1.784	0.427	1.321	0.824-1.917
LSD1 expression	< 0.001	2.456	1.234-3.932	< 0.001	1.426	0.672-2.146

LSD1: Lysine specific demethylase 1; HR: Hazards ratio.